Metagenomi, Inc. (MGX)
- Previous Close
7.75 - Open
7.67 - Bid 6.53 x 100
- Ask 6.81 x 100
- Day's Range
6.86 - 7.88 - 52 Week Range
6.86 - 12.74 - Volume
118,169 - Avg. Volume
225,058 - Market Cap (intraday)
258.56M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.50
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
www.metagenomi.coRecent News: MGX
Compare To: MGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGX
Valuation Measures
Market Cap
287.79M
Enterprise Value
64.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.44
Price/Book (mrq)
--
Enterprise Value/Revenue
1.45
Enterprise Value/EBITDA
-1.16
Financial Highlights
Profitability and Income Statement
Profit Margin
-152.51%
Return on Assets (ttm)
-12.59%
Return on Equity (ttm)
-28.04%
Revenue (ttm)
44.76M
Net Income Avi to Common (ttm)
-68.25M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
271.18M
Total Debt/Equity (mrq)
22.41%
Levered Free Cash Flow (ttm)
-31.65M